HIGHLIGHTS
- who: Sabrina Kepka et al. from the Emergency Department, Strasbourg Regional University Hospital, Place de l`Hu00f4pital, Strasbourg, France have published the Article: A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry, in the Journal: Medicina 2023, 181 of 23/Oct/2013
- what: This study provides evidence that is not only an efficient and safe alternative to VKAs for eligible VTE patients but also cost-saving. The aim of this study was to assess the cost-effectiveness of oral anticoagulants . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.